Chronic Disease Management 2026: Digital Therapeutics, Remote Monitoring, and Value-Based Care

CGM adoption has exploded—from 10% of insulin users in 2015 to 50%+ in 2026. Dexcom G7 and Abbott FreeStyle Libre 3 dominate the market. Key metrics: Time in Range (TIR) 70-180 mg/dL has replaced A1c as the primary optimization target. Real-time alerts prevent hypoglycemia, the most feared complication. Integration with insulin pumps enables automated insulin delivery (AID). Medicare coverage expanded dramatically post-2020; commercial coverage now standard.

AID systems (Omnipod 5, Tandem Control-IQ) combine CGM with insulin pump, using algorithms to automatically adjust insulin. Outcomes: Time in Range increases from 50-60% to 70-80%; hypoglycemia reduced 50%. Hybrid closed-loop (user announces meals) is current standard; fully closed-loop (no meal announcement) in development. Market: 400,000+ users; projected 1M+ by 2028.

Virta Health demonstrated that nutritional ketosis (very low-carbohydrate) combined with continuous remote monitoring can reverse type 2 diabetes—reducing or eliminating insulin and other medications. Clinical outcomes: 60% diabetes reversal at 1 year; 50% medication elimination; $3,000-5,000 annual savings per patient. Value-based contracts with employers and health plans drive adoption. Criticism: sustainability, dietary restrictiveness, long-term adherence.

Better Therapeutics (BT-001) received FDA clearance as a prescription digital therapeutic for type 2 diabetes—software delivering cognitive behavioral therapy (CBT) to address the behavioral roots of diabetes. Reimbursement pathway establishing. Welldoc's BlueStar (FDA-cleared since 2013) is the longest-running DTx platform with established reimbursement. Omada Health dominates the prediabetes space via Medicare Diabetes Prevention Program (MDPP) reimbursement.

48% of U.S. adults have hypertension (120M+), yet only 1 in 4 are controlled. Digital solutions: connected BP monitors (Omron) with automated uploads; digital therapeutics (Hello Heart) delivering lifestyle coaching and medication adherence. Clinical outcomes: Hello Heart demonstrated 10-15 mmHg systolic reduction—comparable to medication addition—with 90% engagement at 12 months. Medicare RPM codes (99453, 99454, 99457, 99458) reimburse $50-150 per month for remote monitoring, making hypertension a profitable RPM condition.

Heart failure affects 6M+ Americans; 30-day readmission rates historically 20-25%—costing $20B+ annually. CMS Hospital Readmission Reduction Program penalizes hospitals with excess readmissions, creating financial incentive for RPM. Biofourmis demonstrates AI predicts exacerbations 7-10 days before hospitalization via analysis of weight, blood pressure, heart rate, symptoms. Early intervention reduces readmissions 50-70%. Medicare RPM reimbursement now covers daily monitoring; value-based contracts share savings.

AFib affects 5M+ Americans; causes 1 in 7 strokes. Mobile ECG devices (AliveCor KardiaMobile) enable detection outside clinical settings. Consumer wearables (Apple Watch, Fitbit) now include AFib detection algorithms. Detection enables anticoagulation, reducing stroke risk 60-70%. Screening protocols evolving; USPSTF currently insufficient evidence for population screening, but high-risk populations benefit.

Traditional cardiac rehab (post-MI, post-CABG) has 20-30% participation rates—barriers include travel, time, accessibility. Digital cardiac rehab programs (MoveStrong, Carda Health) achieve 80%+ completion rates with comparable outcomes. CMS now reimburses digital cardiac rehab (beginning 2024). Market growth accelerating.

Inhaler adherence in asthma and COPD is 30-50%—non-adherence drives exacerbations, hospitalizations, and mortality. Connected inhalers (Propeller, Digihaler) track medication use, provide reminders, and enable clinical review. Clinical outcomes: 40-50% reduction in exacerbations; 30-50% reduction in hospitalizations. Propeller Health (acquired by ResMed) is the category leader with 500,000+ patients. Reimbursement: CPT codes for remote monitoring apply; value-based contracts with payers.

Portable spirometers (connected devices) enable home monitoring of lung function (FEV1, FVC). Wellinks and NuvoAir integrate spirometry with coaching, detecting decline before exacerbations. Early intervention (steroids, antibiotics) reduces hospitalization. Medicare RPM codes apply.

AI models (Propeller, Wellinks) analyze symptom trends, medication use, and spirometry to predict exacerbations. Early warning enables preventive interventions—reducing hospitalizations 30-50%. Machine learning improves accuracy with more data.

Traditional pulmonary rehab (8-12 weeks, supervised exercise) has 2-10% participation rates—barriers include travel, oxygen dependency, comorbidities. Digital pulmonary rehab (Kaia Health) delivers guided breathing exercises, education, and exercise programs via app. Early studies show comparable outcomes to in-person with 80% completion rates. CMS reimbursement for digital pulmonary rehab under development.

37 million Americans have CKD; 90% are undiagnosed until advanced stages. Late diagnosis leads to accelerated progression, earlier dialysis (cost $90,000/year per patient), and higher mortality. Medicare spends $100B+ annually on CKD/ESRD (end-stage renal disease). Value-based care models are transforming CKD management—moving from reactive dialysis care to proactive progression prevention.

AI models (Renalytix KidneyIntelX) analyze eGFR, urine albumin, and clinical data to predict which CKD patients will progress rapidly (30-50% eGFR decline within 2-5 years). Early identification enables intensive management—SGLT2 inhibitors, blood pressure control, dietary intervention—slowing progression 30-50%.

Strive Health, Monogram Health, and Cricket Health (now Interwell) contract with Medicare Advantage plans and commercial payers to manage CKD populations under value-based agreements. Services include: care coordination, medication management (SGLT2i, ACEi/ARB), dietary counseling, social determinants navigation, and palliative care. Outcomes: slowed eGFR decline, 30-50% reduction in hospitalizations, delayed dialysis starts (2-3 years).

SGLT2 inhibitors (empagliflozin, dapagliflozin) originally developed for diabetes now show profound kidney protection in non-diabetic CKD—slowing progression 30-40%, reducing heart failure hospitalizations. Digital platforms ensure appropriate prescribing and adherence.

Home dialysis (peritoneal dialysis, home hemodialysis) has superior outcomes and lower cost than in-center hemodialysis. Digital platforms (Monogram, Cricket) support home dialysis adoption through training, remote monitoring, and 24/7 support. Medicare encourages home dialysis through payment incentives.

DTx are FDA-cleared software applications that deliver evidence-based therapeutic interventions to prevent, manage, or treat medical conditions. Unlike wellness apps, DTx undergo rigorous clinical trials, require prescription, and seek insurance reimbursement. DTx address the behavioral, cognitive, and lifestyle roots of chronic disease—complementing or replacing pharmaceuticals.

Better Therapeutics (BT-001) received FDA clearance in 2023 for type 2 diabetes—software delivering cognitive behavioral therapy (CBT) via mobile app. Clinical trials: 1.0-1.5% A1c reduction (comparable to adding a medication). BlueStar (Welldoc) has been prescribed since 2013, with established commercial reimbursement. Omada Health's Medicare Diabetes Prevention Program (MDPP) is reimbursed by CMS for prediabetes—demonstrating the DTx reimbursement pathway.

DTx reimbursement has been the industry's greatest challenge. Current landscape:

Pear Therapeutics (reSET, reSET-O for substance use disorder) was the first DTx company to go public via SPAC ($1.6B valuation). Filed for bankruptcy in 2023. Lessons: Reimbursement is slower than expected; commercial payers hesitant to cover DTx without established pathways; high customer acquisition costs; need for integration with clinical workflows.

DTx require prescription by licensed clinicians. Integration with EHRs enables prescribing workflows. Pharmacy channels (CVS, Walgreens) are developing DTx fulfillment. Adherence remains challenge—engagement is required for efficacy.

Medicare RPM codes (99453, 99454, 99457, 99458) created the economic foundation for digital chronic care:

Total: $150-250 per patient monthly. 50+ commercial payers have adopted similar codes. This reimbursement has driven RPM adoption—2M+ Medicare patients now receive RPM services.

Biofourmis exemplifies AI-powered RPM: patients wear a biosensor (temperature, heart rate, respiratory rate, activity, symptoms). AI learns individual baselines; detects deviations (e.g., weight gain, HR changes) that predict heart failure exacerbation 7-10 days before hospitalization. Early intervention (diuretic adjustment, medication change) prevents hospitalization. Validation: 50-70% reduction in readmissions.

Consumer wearables (Apple Watch, Fitbit, Oura) are increasingly integrated into RPM programs:

Challenge: FDA clearance for clinical decision-making varies; data integration with EHRs remains fragmented.

CMS Acute Hospital Care at Home waiver (initiated during COVID, extended) enables hospital-level care at home. RPM (vitals monitoring, daily video visits) supports safe home care. Conditions: heart failure, COPD, pneumonia, post-surgical. Outcomes: 30% lower cost, 50% fewer readmissions, high patient satisfaction. 300+ hospitals now offer hospital-at-home.

50% of Medicare beneficiaries (30M+) are now enrolled in Medicare Advantage (MA) plans. MA plans receive capitated payments from CMS (fixed $ per member per month) and bear financial risk for beneficiary care. This creates strong incentive to invest in chronic disease management programs that reduce hospitalizations, ER visits, and total cost of care. Digital health companies (Omada, Livongo, Biofourmis) contract with MA plans, sharing in cost savings.

ACOs are groups of providers (physicians, hospitals) that coordinate care for Medicare beneficiaries. CMS tracks quality and cost; ACOs that achieve savings share in them. 500+ ACOs cover 15M+ beneficiaries. ACOs invest in RPM, care coordination, and digital therapeutics to improve outcomes and reduce utilization.

CMS Innovation Center (CMMI) launched KCC to improve kidney care and delay dialysis. Participating organizations receive capitated payments and share in savings for managing CKD populations. Strive Health, Monogram Health, and Healthmap Solutions are KCC participants driving CKD innovation.

MDPP reimburses CDC-recognized organizations for delivering structured prediabetes interventions (Omada Health, etc.). Payment is tied to outcomes: session attendance, weight loss (5% weight loss triggers payment). This established a precedent for reimbursing digital therapeutics based on outcomes rather than service delivery.

Large employers are increasingly self-insured, bearing financial risk for employee health. They contract with digital health vendors (Omada, Livongo, etc.) under value-based arrangements—payment tied to engagement, clinical outcomes, and total cost reduction. Insurers (UnitedHealth, Humana, etc.) have internal VBC programs and external partnerships.

AI will move from predicting exacerbations to preventing them. Machine learning models analyzing continuous data (wearables, EHR, social determinants) will identify patients at highest risk and trigger automated interventions (medication adjustment, care team outreach, home visits). Prediction windows will extend from 7-10 days to months, enabling true prevention.

Virtual-first care models (Omada, Virta, etc.) will become the default for chronic disease management, with in-person care reserved for procedures and complex cases. Integrated platforms will combine RPM, DTx, coaching, medication management, and specialist consultation. 50% of chronic disease management expected virtual by 2030.

CGM for diabetes is the prototype—continuous monitoring for blood pressure, heart rhythm, respiratory function, and kidney function will become standard. Implantable sensors (e.g., for heart failure pressure monitoring) will expand. Passive monitoring (motion sensors, sleep tracking, weight scales) will reduce patient burden.

Permanent CPT codes for DTx will establish reimbursement pathways. Major health plans will cover DTx as standard benefit. Combination DTx-drug products will emerge—software that enhances medication efficacy or adherence. DTx will be prescribed and filled through pharmacy channels.

Genomics, proteomics, and metabolomics will stratify patients for targeted interventions. Example: genetic variants predicting response to GLP-1 agonists will guide diabetes treatment selection. Digital platforms will integrate biomarker data to personalize coaching and medication.

Health plans and providers will invest in addressing social determinants (food insecurity, housing instability, transportation) as medical interventions. Digital platforms will screen, refer, and track social needs. Value-based models will incentivize social determinants investment.

CMS Acute Hospital Care at Home waiver will become permanent. 30-50% of acute care will shift to home by 2030—enabled by RPM, home infusions, and mobile diagnostics. Chronic disease management will integrate with acute care at home.